Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more
Shenzhen Weiguang Biological Products Co Ltd (002880) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.022x
Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has a cash flow conversion efficiency ratio of 0.022x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥51.60 Million) by net assets (CN¥2.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Weiguang Biological Products Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Harbin Group of Technology Corp. A
SHG:688459
|
N/A |
|
Gladstone Land Corporation 6.00% Series C Cumulative Redeemable Preferred Stock
NASDAQ:LANDP
|
0.005x |
|
Relaxo Footwears Limited
NSE:RELAXO
|
0.112x |
|
Beneteau SA
LSE:0K8N
|
0.016x |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
0.024x |
|
MBK Public Company Limited
BK:MBK
|
0.069x |
|
Pico Far East Holdings Limited
F:PJFB
|
0.052x |
|
Advanced International Multitech Co Ltd
TWO:8938
|
0.058x |
Annual Cash Flow Conversion Efficiency for Shenzhen Weiguang Biological Products Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.24 Billion | CN¥177.77 Million | 0.079x | -59.28% |
| 2023-12-31 | CN¥2.05 Billion | CN¥397.94 Million | 0.195x | +30198.49% |
| 2022-12-31 | CN¥1.87 Billion | CN¥1.20 Million | 0.001x | -99.53% |
| 2021-12-31 | CN¥1.79 Billion | CN¥246.89 Million | 0.138x | -26.25% |
| 2020-12-31 | CN¥1.62 Billion | CN¥303.96 Million | 0.187x | +46.04% |
| 2019-12-31 | CN¥1.45 Billion | CN¥185.70 Million | 0.128x | +68.15% |
| 2018-12-31 | CN¥1.31 Billion | CN¥99.54 Million | 0.076x | +220.52% |
| 2017-12-31 | CN¥1.20 Billion | CN¥28.61 Million | 0.024x | -90.47% |
| 2016-12-31 | CN¥506.44 Million | CN¥126.41 Million | 0.250x | -34.53% |
| 2015-12-31 | CN¥393.71 Million | CN¥150.09 Million | 0.381x | -12.24% |
| 2014-12-31 | CN¥308.86 Million | CN¥134.17 Million | 0.434x | +364.69% |
| 2013-12-31 | CN¥223.88 Million | CN¥20.93 Million | 0.093x | -89.11% |
| 2012-12-31 | CN¥135.00 Million | CN¥115.88 Million | 0.858x | -- |